Future multibillion-dollar obesity market will be dominated by Novo and Lilly, bank predicts
Players are beginning to position themselves as a very lucrative market for weight-loss drugs matures, but Morgan Stanley believes the two rivals Novo Nordisk and Eli Lilly will take almost half.
by marketwire, translated by daniel pedersen
Eli Lilly, Amgen, and a number of other companies are seeking to challenge Novo Nordisk on the obesity market, which is facing a demand boom in coming years, investment bank Morgan Stanley assesses according to media Financial Times.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly eyes unprecedented demand for Mounjaro
For subscribers
